DailyIQ
Last updatedUpdating…

BSX·Boston Scientific Corporation

$42.34
+0.15 (+0.36%)
High
$42.52
Open
$42.19
Market Cap
62.07B
52W High
$105.65
Low
$41.81
P. Close
$42.34
P/E
16.89
52W Low
$41.49
Fwd P/E
12.40
DailyIQ Est.
$65.66
Inst. Ownership
45.6%
Short Interest
3.16%
Days to Cover
2.4
Technical Score (1D)
5
BEARISH
News Sentiment
49
MIXED
On Oct 7, Boston Scientific announced that Joseph M. Fitzgerald would become Executive Vice President and Chief Operating Officer effective Jan. 1, 2027. On Oct 7, the company also introduced a new three‑segment reporting structure—Interventional Therapies, Rhythm Solutions, and MedSurg—to streamline decision making and allocate capital more effectively. On Oct 6, a comparison article reported that Boston Scientific’s shares had fallen more sharply over the past year than Stryker’s. On Oct 6, the same article noted that Boston Scientific reported higher gross and net margins than Stryker, with gross margins of 69.19% versus 65.59% and net margins of 17.50% versus 14.43%. On Oct 6, the article also mentioned that revenue growth rates were comparable, with Boston Scientific at 9.40% quarterly growth and Stryker slightly lower. The new leadership and reporting changes on Oct 7 are intended to support continued growth and enhance operational coordination across the firm’s global business units. The comparison on Oct 6 highlights that despite stronger margins, Boston Scientific’s share price decline was steeper, suggesting that market performance may not directly reflect profitability metrics.
LOW TARGET
$44 +3.9%
2 analysts
MEAN TARGET
$61 +43.6%
12 analysts
HIGH TARGET
$94 +122.0%
26 analysts
PRICE RANGE
$44.00 - $94.00
SB / B / H / S / SS
11/19/8/1/1
DAILYIQ EST.
$65.66 (+55.1%)
Sector
Healthcare
Industry
Medical Devices
Exchange
NYQ
Country
United States
Symbol
BSX
Description
Boston Scientific Corporation is a global medical device manufacturer specializing in interventional medical specialties. The company's core business involves developing, manufacturing, and marketing a diverse portfolio of devices used in the MedSurg and Cardiovascular segments. These offerings span a wide range of applications, including gastrointestinal, urological, and neurological treatments, as well as devices for managing chronic pain. Boston Scientific also provides critical technologies for diagnosing and treating cardiovascular diseases, including coronary artery disease and aortic valve conditions, along with devices for heart rhythm management and peripheral arterial disease. Incorporated in 1979, the company is headquartered in Marlborough, Massachusetts.
Bought (1Y)
206,362 shares
$10.0M
Sold (1Y)
1,577 shares
$71K
O'Connor Padraig AndrewEVP, Global Operations
Option Exercise1,171 shares2026-09-02
O'Connor Padraig AndrewEVP, Global Operations
Tax Withholding567 shares2026-09-02
O'Connor Padraig AndrewEVP, Global Operations
Option Exercise1,171 shares2026-09-02
Morano Susan E-
Buy2,040 shares2026-08-25
Woodworth EmilySVP, Global Controller and CAO
I2,930 shares2026-08-11
87/ 100
Strong bullish
Overall: Bullish
✓Revenue growing year over year
✓Positive net margin
✓Positive operating cash flow
Gross Margin
69.0%
Net Margin
14.4%
Revenue CAGR
5.0%
Current Ratio
1.62x
Debt / Equity
0.47x
Return on Equity
11.9%
Earnings Summary
Boston Scientific Corporation is a global medical device manufacturer focused on interventional specialties, offering a broad portfolio across gastrointestinal, urological, neurological, chronic pain, and cardiovascular segments, including coronary and aortic valve technologies. The company operates within the highly regulated healthcare sector, where product innovation and regulatory approvals drive growth. In the most recent quarters, Boston Scientific reported EPS of $0.75 in Q1 2025, $0.75 in Q2 2025, and $0.80 in Q3 2025, consistently beating analyst estimates of $0.67251, $0.72522, and $0.71366 respectively; revenue rose from $4.66 billion in Q1 2025 to $5.065 billion in Q3 2025, reflecting a 9.5% YoY increase. The company maintained a pattern of EPS beats in four consecutive quarters, while revenue growth accelerated from 8.4% in Q1 2025 to 9.5% in Q3 2025, indicating robust top‑line momentum. Historically, Boston Scientific has delivered double‑digit revenue growth over the past five years, with EPS growth lagging slightly but still positive; the firm has consistently outperformed estimates in the last six quarters, underscoring disciplined cost management and product pipeline strength. Recent news highlights a modest downward revision of the organic growth forecast to 5‑6% by the company on Oct 3, reflecting caution amid market uncertainties, and Citigroup’s price target cut to $48 on Oct 5, signaling a slight negative view on near‑term prospects; these developments may temper investor enthusiasm but do not alter the underlying earnings trend.

EPS

EstBeatMiss
$0.69$0.74$0.79$0.83$0.88Q2'25Q3'25Q4'25Q1'26Q2'26Q3'26
QtrEstActual+/−
Q3'26$0.76 - -
Q2'26$0.83$0.86+3.9%
Q1'26$0.79$0.80+1.6%
Q4'25$0.79$0.80+1.6%
Q3'25$0.71$0.75+5.1%
Q2'25$0.73$0.75+3.4%

Revenue

EstBeatMiss
$5.0B$5.1B$5.3B$5.4B$5.5BQ2'25Q3'25Q4'25Q1'26Q2'26Q3'26
QtrEstActual+/−
Q3'26$5.2B - -
Q2'26$5.4B$5.4B+0.5%
Q1'26$5.2B$5.2B+0.6%
Q4'25$5.3B$5.3B-0.9%
Q3'25 - $5.1B -
Q2'25 - $5.1B -

Market Data

BSX Stock Snapshot

BEARISH5/100
$42.34+$0.15 (0.4%)
Market cap
62.07B
P/E ratio
16.9
Day range
$41.81 – $42.52
News sentiment
49/100 · Neutral
Analyst target
$60.79 (+43.6%)
Consensus
Buy · 40 analysts
52-week range+2.0% off low · -59.9% from high
$41.49$105.65
Price $42.34 DailyIQ Est. $65.66

BSX is on the weaker side of its setup, with little confirmation for a reversal yet. The stock is liquid enough that positioning changes get absorbed without distorting the trend.

Reverse DCF

What growth is priced into BSX?

CHEAP

At today's price, Boston Scientific Corporation needs to grow free cash flow about 4.4% a year for the next 10 years to justify its valuation at a 8.11% cost of capital. Over its actual history it has compounded free cash flow at 10.7% a year, so the market is asking for 6.3 percentage points below its own delivered rate. On that basis BSX looks priced below what its own growth record supports.

Implied FCF growth
4.4%
Historical FCF CAGR
10.7%
Growth gap
-6.3 pts
Verdict
CHEAP
Discount rate (WACC)
8.11%
Beta
0.77

Behaviour On Record

What BSX's own history says about today's numbers

Realized volatility (21d)
32.7% 81st pct
Below its peak
-61.0%
vs 200-day average
-31.4%
Up days (1y)
46%

Boston Scientific Corporation is currently running 32.7% annualised volatility over the last 21 sessions. Measured against BSX's own 13 years of daily returns rather than a market-wide average, that is the 81st percentile — elevated for this stock, against a typical reading of 23.4%. The distinction matters because a number that looks calm for one stock is turbulent for another, and the absolute figure on its own tells you neither.

BSX is trading -61.0% below its running peak. Across 12 full years on file, its median worst-drawdown-in-a-year was -17.7%, and the deepest was -42.5% in 2020. The current drawdown is already deeper than this stock's typical annual low point, which puts it in the part of its range where past recoveries began — and where past declines also continued.

Price sits -31.4% from its 200-day moving average. Against every other day in its history, that gap ranks at the 3rd percentile — a narrower gap than it typically runs. Over the past year BSX closed higher on 46% of sessions, and it is currently 3 sessions into a falling streak.

On October specifically: over 13 years of records, BSX finished the month higher 6 of 13 times, with a median return of -0.6% and an average of +0.4%. Its strongest month historically has been January at +5.5% on average, its weakest September at -2.3%. Seasonality is a weak signal on its own — a decade is a small sample and regimes change — but it is a real distribution rather than a rule of thumb.

Overnight risk is measurable too: BSX has opened more than 2% away from the prior close in 123 of 3,267 sessions (3.8% of the time), with the largest gaps running +9.8% and -9.7%. For anyone holding through an event, that rate is a better guide to overnight exposure than the intraday range.

Across the last 3 dated reports on file, BSX moved an average of 1.4% in the session after earnings, closing higher 2 of those 3 times, with a median move of +1.5% and a largest of +2.1%.

All figures computed from 3,268 daily closes between 2013-10-07 and 2026-10-05, split-adjusted, recomputed daily. Percentiles are against BSX's own 13-year history, not a peer group or index.

Sector Rotation

Is money rotating into or out of BSX's sector?

Boston Scientific Corporation sits in the Health Care sector, currently ranked 3rd of 12 GICS sectors by relative-strength rotation score (weakening). Within its narrower Medical Devices industry group, BSX ranks 3rd of 15 tracked industries, lagging.

Sector rank
#3 of 12
Sector state
Weakening
Sector rotation score
82
Industry rank
#3 of 15

Options Market

What is the options market pricing for BSX?

CallsPuts

For Boston Scientific Corporation's nearest expiry (2026-10-09, 2 days out), open interest is roughly balanced between puts and calls (put/call ratio of 0.90), with at-the-money implied volatility around 58.4%. The options market is pricing roughly a ±3.2% move by that expiry — a range of about $40.57–$43.21.

Put/call ratio (2026-10-09)
0.90
ATM implied volatility
58.4%
Total open interest
9,736
Expected move by 2026-10-09
±3.2% ($40.57–$43.21)

Analyst Rating Changes

Are analysts turning bullish or bearish on BSX?

Wells Fargo most recently reiterated its rating on Boston Scientific Corporation to Equal-Weight on Sep 24, 2026 with a price target of $48 (from $50). Over the last 90 days, coverage has run 0 upgrades against 2 downgrades, a net bearish lean.

Latest action
Wells Fargo — Equal-Weight
90-day upgrades
0
90-day downgrades
2
Net rating momentum
-2
DateFirmActionRatingPrice target
Sep 24, 2026Wells FargoMaintainedEqual-Weight$50 → $48
Sep 21, 2026OppenheimerMaintainedOutperform$85 → $65
Sep 17, 2026CitigroupDowngradeBuy → Neutral$57 → $50
Sep 9, 2026BTIGMaintainedBuy$60 → $56
Aug 25, 2026TD CowenReiteratedBuy$56
Jul 31, 2026Argus ResearchDowngradeBuy → Hold-
Jul 30, 2026UBSMaintainedBuy$74 → $67
Jul 30, 2026CitigroupMaintainedBuy$70 → $61
Jul 30, 2026RBC CapitalMaintainedOutperform$85 → $70
Jul 30, 2026TD CowenMaintainedBuy$61 → $56
Jul 30, 2026Canaccord GenuityMaintainedBuy$70 → $66
Jul 30, 2026Truist SecuritiesMaintainedBuy$62 → $57

BSX Competitive Positioning

Boston Scientific Corporation (BSX) is tracked alongside these names in Medical Devices on DailyIQ — ranked by market cap, with today's move alongside.

News Sentiment Analysis

Sentiment gathered from recent headlines

49/100
Strong NegativeNeutralStrong Positive
MIXED

Recent News Coverage

Most recent articles, ranked by recency (click to expand).

10+ articles
What did this article say?
Boston Scientific announced on October 7 that Joseph Fitzgerald would assume the role of chief operating officer. Fitzgerald brings extensive experience from previous executive positions in the medical device sector, which the company highlighted as a strategic fit for its operational goals. The appointment is part of the firm’s ongoing leadership refresh aimed at sustaining growth and improving operational efficiency. No immediate financial guidance or earnings impact was disclosed, suggesting the change is a routine management update.
What did this article say?
Boston Scientific announced on October 7, 2026 that Joseph M. Fitzgerald would become Executive Vice President and Chief Operating Officer effective January 1, 2027. The company also introduced a new three‑segment reporting structure—Interventional Therapies, Rhythm Solutions, and MedSurg—to streamline decision making and allocate capital more effectively. Fitzgerald’s appointment is intended to support continued growth and enhance operational coordination across the firm’s global business units.
What did this article say?
The article compares Boston Scientific (BSX) and Stryker (SYK) on share price performance and profitability metrics. Boston Scientific’s shares fell more sharply over the past year, yet the company reported higher gross and net margins than Stryker. Revenue growth rates for both companies were similar, with BSX slightly ahead. The piece notes that the stronger margins of BSX may explain its steeper share price decline. No material corporate actions or guidance changes were disclosed.
What did this article say?
Citigroup reduced its price target for Boston Scientific (BSX) from $50 to $48 while keeping a neutral rating. The bank cited modest valuation concerns and a more cautious outlook on the company’s earnings trajectory. The downgrade signals a slight negative view on BSX’s near‑term prospects, though the overall stance remains unchanged. This adjustment may influence short‑term investor sentiment but is unlikely to trigger a major market move.
What did this article say?
Boston Scientific (BSX) announced a significant reduction in its organic growth forecast, halving the outlook to a range of 5-6%. The decision reflects a cautious stance amid broader market uncertainties and competitive pressures. Analysts noted that the downgrade may impact investor sentiment and valuation multiples. The move underscores the company's focus on cost control and strategic realignment. Overall, the announcement signals a modest headwind for BSX’s future earnings trajectory.
What did this article say?
Boston Scientific (BSX) closed at $42.60, down 1.46% on Oct 2, trailing the S&P 500's 0.73% gain. The medical device firm has lost 7.92% over the past month, while the broader medical sector fell 3.74%. Investors are watching the upcoming earnings release on Oct 28, where analysts forecast $0.76 per share and $5.23 billion revenue, modest year‑over‑year growth. The consensus estimates project full‑year earnings of $3.25 per share and revenue of $21.22 billion, a 6.21% and 5.72% increase respectively. The market reaction reflects a short‑term negative sentiment despite the positive earnings outlook.
What did this article say?
Boston Scientific (BSX) achieved an average annual return of 14.35% over the past 15 years, outperforming the market by 1.13% on an annualized basis. The company’s market capitalization remains robust, reflecting sustained investor confidence. The performance highlights the firm’s consistent growth and effective execution of its strategic initiatives. No new catalysts or guidance changes were disclosed, indicating a steady but positive trajectory.
What did this article say?
Elutia announced it had received the full $8 million escrow payment from Boston Scientific following the sale of its BioEnvelope business. The payment closed an indemnity holdback that began with the $88 million transaction in October of the previous year. With the funds now in hand, Elutia is fully funded through the first year of its anticipated NXT‑41x launch and into 2029, and expects a favorable FDA clearance in the first half of 2027.

Technical Analysis

Real-time indicators across multiple timeframes

5
BEARISH
Technical indicators reflect the latest computed signal mix for this timeframe.
Unlock full technicals
Create a free account to access more indicators and deeper timeframe data.
Institutional & Hedge Fund Ownership
25 tracked managers · $35.50B combined position · 12 adding, 11 trimming, 2 unchanged (latest 13F filings)
ManagerTrendShares Held% of Co.Position ValueFiled
Vanguard Group Inc▲ Buy139,685,9979.49%$13.32B2026-01-29
BlackRock, Inc.▼ Sell129,680,9168.81%$5.53B2026-08-07
FMR LLC (Fidelity)▼ Sell45,702,8453.11%$1.95B2026-08-13
Geode Capital Management, LLC▲ Buy33,440,1022.27%$1.42B2026-08-12
JPMorgan Chase & Co▼ Sell28,133,0381.91%$1.22B2026-08-12
D. E. Shaw & Co., Inc.▲ Buy27,267,2091.85%$1.16B2026-08-14
Janus Henderson Group plc• Hold16,497,3661.12%$1.04B2026-05-18
Norges Bank▼ Sell21,170,0291.44%$903.54M2026-08-12
Two Sigma Investments, LP▲ Buy19,420,3231.32%$828.86M2026-08-14
Goldman Sachs Group Inc▼ Sell19,207,7421.31%$819.79M2026-08-14
Morgan Stanley▼ Sell18,947,1471.29%$808.66M2026-08-13
Capital World Investors▲ Buy16,812,2571.14%$717.60M2026-08-12
Wellington Management Group LLP▼ Sell15,301,8281.04%$653.08M2026-08-14
Capital Research Global Investors▲ Buy14,180,5710.96%$605.26M2026-08-12
Invesco Ltd.▲ Buy13,800,7480.94%$589.02M2026-08-14
Bank of America Corp▼ Sell13,027,7830.89%$556.03M2026-08-14
Northern Trust Corp▼ Sell12,964,6380.88%$553.33M2026-08-13
Egerton Capital (UK) LLP▲ Buy5,385,0840.37%$513.47M2026-02-11
Farallon Capital Management LLC▲ Buy10,521,1840.72%$449.04M2026-08-14
Citadel Advisors LLC• Hold10,155,3480.69%$433.43M2026-09-02
AQR Capital Management LLC▲ Buy9,681,7500.66%$413.22M2026-08-14
Susquehanna International Group, LLP▼ Sell6,554,4500.45%$279.74M2026-08-14
Maverick Capital Ltd▲ Buy5,937,5530.40%$253.41M2026-08-14
Viking Global Investors LP▼ Sell2,509,8080.17%$239.31M2026-02-17
Millennium Management LLC▲ Buy5,938,8670.40%$232.13M2026-08-14
Q2 2026 flow:35.18M sh bought ($1.50B)56.57M sh sold ($2.42B)net -21.39M sh (−$920.12M)
Congressional Trading Activity
25 disclosed trades · ~$383.0K est. traded value · 11 buys, 14 sells
MemberChamberStateTypeAmountTradedFiled
Kevin HernHouseOK01▼ Sell$50K - $100K2026-09-092026-09-25
Kevin HernHouseOK01▼ Sell$50K - $100K2026-09-042026-09-25
Kevin HernHouseOK01▼ Sell$1K - $15K2026-09-032026-09-25
Kevin HernHouseOK01▼ Sell$15K - $50K2026-08-312026-09-25
Gilbert CisnerosHouseCA31▲ Buy$1K - $15K2026-08-182026-09-10
Gilbert CisnerosHouseCA31▲ Buy$1K - $15K2026-06-052026-07-02
Gilbert CisnerosHouseCA31▼ Sell$1K - $15K2026-06-052026-07-02
John BoozmanSenateAR▼ Sell$1K - $15K2026-06-042026-07-13
Gilbert CisnerosHouseCA31▲ Buy$1K - $15K2026-05-292026-06-08
Gilbert CisnerosHouseCA31▲ Buy$1K - $15K2026-05-192026-06-08
Gilbert CisnerosHouseCA31▲ Buy$1K - $15K2026-05-112026-06-08
Alan ArmstrongSenateOK▲ Buy$1K - $15K2026-03-272026-07-21
Gilbert CisnerosHouseCA31▲ Buy$1K - $15K2026-02-102026-03-09
Gilbert CisnerosHouseCA31▲ Buy$1K - $15K2026-01-302026-02-13
Gilbert CisnerosHouseCA31▼ Sell$1K - $15K2025-12-242026-01-12
John BoozmanSenateAR▼ Sell$1K - $15K2025-12-172026-01-13
Gilbert CisnerosHouseCA31▲ Buy$1K - $15K2025-11-182025-12-15
Lisa McClainHouseMI09▼ Sell$1K - $15K2025-10-312025-11-21
Lisa McClainHouseMI09▼ Sell$1K - $15K2025-10-302025-11-21
Lisa McClainHouseMI09▲ Buy$1K - $15K2025-10-302025-11-21
Kevin HernHouseOK01▼ Sell$15K - $50K2025-10-282025-11-16
Gilbert CisnerosHouseCA31▲ Buy$1K - $15K2025-10-172025-11-18
Valerie HoyleHouseOR04▼ Sell$1K - $15K2025-09-232025-10-10
Lisa McClainHouseMI09▼ Sell$1K - $15K2025-08-042025-09-12
Gilbert CisnerosHouseCA31▼ Sell$1K - $15K2025-07-312025-08-14